New Clinical Trial: Targeted Therapy and Avelumab in Merkel Cell Carcinoma (NCT04261855)
WHY IT MATTERS
This trial offers patients with metastatic Merkel cell carcinoma access to a novel combination therapy that may provide additional treatment options beyond standard care, though enrollment is currently closed.
Researchers are testing a new combination treatment for metastatic Merkel cell carcinoma, a rare type of skin cancer. The study combines a drug called avelumab with either a radioactive therapy or radiation treatment. The trial is currently enrolling patients and aims to see if this combination is safe and effective at fighting the cancer.
NCT ID: NCT04261855 Status: ACTIVE_NOT_RECRUITING Conditions: Metastatic Merkel Cell Carcinoma Phase: PHASE1, PHASE2 Enrollment: 19 Sponsor: Melanoma and Skin Cancer Trials Limited Summary: 10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).
ASK YOUR DOCTOR
Ask your oncologist if you have metastatic Merkel cell carcinoma whether you might be eligible for this trial or if similar combination approaches are being considered in your treatment plan.